Literature DB >> 1881995

Chronic treatment with chlorpromazine, thioridazine or haloperidol increases striatal enkephalins and their release from rat brain.

Z S Herman1, M Huzarska, K Kmieciak-Kolada, J Kowalski.   

Abstract

The aim of this paper is to study the effect of 1, 2 or 3 months' administration of chlorpromazine (CPZ), thioridazine (TDZ) (2 or 6 mg/kg) or haloperidol (HAL) (0.25 or 1 mg/kg) IP on the level of leu- and met-enkephalin (ENK) in striatum. A dose- and time-dependent increase of striatal ENK level was observed after chronic administration of the neuroleptics (NL), but 8 days after withdrawal of chronically administered NL striatal ENK was decreased. Apomorphine pretreatment significantly attenuated the elevation in ENK produced by chronic injections of NL. In perfusion fluid obtained from the lateral ventricle of animals treated 1 month with HAL a dose-dependent increase of ENK levels was observed, which was augmented by potassium ions. It is concluded that: 1) Chronic administration of neuroleptic drugs that block dopamine receptors increases the level and the release of striatal enkephalins; 2) The results support the hypothesis that activation of dopaminergic neurons tonically inhibits the synthesis of enkephalins in the striatum.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1881995     DOI: 10.1007/bf02244563

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  54 in total

1.  Mu-, delta- and kappa-opioid receptor-mediated inhibition of neurotransmitter release and adenylate cyclase activity in rat brain slices: studies with fentanyl isothiocyanate.

Authors:  A N Schoffelmeer; K C Rice; A E Jacobson; J G Van Gelderen; F Hogenboom; M H Heijna; A H Mulder
Journal:  Eur J Pharmacol       Date:  1988-09-13       Impact factor: 4.432

2.  Dopaminergic regulation of striatal proenkephalin mRNA and prodynorphin mRNA: contrasting effects of D1 and D2 antagonists.

Authors:  B J Morris; V Höllt; A Herz
Journal:  Neuroscience       Date:  1988-05       Impact factor: 3.590

3.  Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects.

Authors:  S H Snyder; D Greenberg; H I Yamumura
Journal:  J Psychiatr Res       Date:  1974       Impact factor: 4.791

4.  Presynaptic dopamine receptors. Development of supersensitivity following treatment with fluphenazine decanoate.

Authors:  M C Nowycky; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

5.  Regulation of striatal enkephalin turnover in rats receiving antagonists of specific dopamine receptor subtypes.

Authors:  I Mocchetti; J R Naranjo; E Costa
Journal:  J Pharmacol Exp Ther       Date:  1987-06       Impact factor: 4.030

6.  Long-term haloperidol-treatment of mice: a change in beta-adrenergic receptor responsiveness.

Authors:  R Dunstan; D M Jackson
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

7.  Inhibition of dopamine-sensitive adenylate cyclase by opioids: possible involvement of physically associated mu- and delta-opioid receptors.

Authors:  A N Schoffelmeer; F Hogenboom; A H Mulder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-03       Impact factor: 3.000

8.  An inhibitor of opioid peptide degradation produces analgesia in mice.

Authors:  W H Simmons; R F Ritzmann
Journal:  Pharmacol Biochem Behav       Date:  1980-11       Impact factor: 3.533

9.  The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice.

Authors:  B P Roques; M C Fournié-Zaluski; E Soroca; J M Lecomte; B Malfroy; C Llorens; J C Schwartz
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

10.  Effects of apomorphine on morphine analgesia during the state of dopaminergic supersensitivity after chronic treatment with haloperidol.

Authors:  K Kamata; K Ogawa; S Noma; T Kameyama
Journal:  J Pharmacobiodyn       Date:  1986-01
View more
  2 in total

1.  Involvement of the rat caudate nucleus in the immunostimulatory effect of DAGO.

Authors:  L V Devoino; M A Cheido; E L Al'perina
Journal:  Neurosci Behav Physiol       Date:  2001 May-Jun

2.  The differential contribution of dopamine D(1) and D (2) receptors to mu-opioidergic immunomodulation.

Authors:  M A Cheido; G V Idova
Journal:  Neurosci Behav Physiol       Date:  2007-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.